ClinicalTrials.gg
CompletedNCT01332201Updated Jun 16, 2015

Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®

A Phase 2 interventional study of Advagraf and Prograf in Heart Transplantation, Lung Transplantation and Pancreas (Including SPK) Transplantation, sponsored by Astellas Pharma Inc. Completed at 8 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-16.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Comparison of tacrolimus blood levels in adults who have received a transplant and are taking either Prograf or Advagraf anti-rejection therapy immediately following surgery. This is followed by checking of safety and effectiveness for one year.

02

Conditions studied

  • Heart Transplantation
  • Lung Transplantation
  • Pancreas (Including SPK) Transplantation

Keywords

  • Advagraf
  • Heart
  • Lung
  • Pancreas
  • Transplant
  • Immunosuppression
  • Pharmacokinetics
03

In context

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must receive first oral dose of tacrolimus one day (lung, pancreas or Simultaneous Pancreas Kidney (SPK) recipients) or three days (heart recipients) after transplantation (skin closure)
  • negative pregnancy test prior to enrolment (females)
  • agree to practice effective during the study
  • treated since transplantation with Antithymocyte globulin/ Mycophenolate Mofetil/ (ATG/MMF/steroids), gastric motility resumed and renal function adequate (\<230 µmol/l (\<2.6 ml/dl)) on Day 1

Exclusion criteria

Exclusion Criteria:

  • receiving a multi-organ transplant (with the exception of SPK) or previously received an organ transplant (including re-transplantation)
  • pulmonary vascular resistance ≥4 Wood units despite medication
  • required an emergency ventricular assist device within one week prior to transplantation
  • significant renal impairment
  • significant liver disease
  • or a history of malignancy within the last 5 years
  • significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus, or active peptic ulcer
  • requires systemic medication for any other indication than transplantation
  • diagnosis of cystic fibrosis
  • pregnant or breast-feeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Advagraf

    Drug: Advagraf

  • Active comparator
    Prograf

    Drug: Prograf

Interventions

  • oral

    Also known as: FK506E, MR4, tacrolimus modified release

  • oral

    Also known as: tacrolimus, FK506

06

What researchers measure

Primary outcomes

  1. determine steady state systemic exposure (AUC 0-24h)

    Time frame: Day 1, Day 3, Day 7 and Day 42

Secondary outcomes

  1. determine Cmax (maximum concentration)

    Time frame: Day 1, Day 3, Day 7 and Day 42

  2. determine tmax (time to attain Cmax)

    Time frame: Day 1, Day 3, Day 7 and Day 42

  3. determine C24 (concentration prior to next morning dose)

    Time frame: Day 1, Day 3, Day 7 and Day 42

  4. describe rejection episodes

    Time frame: up to 58 weeks

  5. describe subject survival

    Time frame: up to 58 weeks

  6. describe graft survival

    Time frame: up to 58 weeks

07

Study locations

8 sites
  • Vienna, Austria
  • Leuven, Belgium
  • Paris, France
  • Milan, Italy
  • Padova, Italy
  • Taipei, Taiwan
  • London, United Kingdom
  • Manchester, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 11, 2011
Start
Jul 2011
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Jun 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332201
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
Jul 2011
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Jun 16, 2015

Study contacts

Use Central Contact
study chair · Astellas Pharma Europe Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion